This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
KUALA LUMPUR: The FBM KLCI’s worst quarterly performance since 2011 has dragged its performance for the first half of 2018 (1H18) into the red with a decline of 5.9% year to date. The benchmark index fell by 9.23% in the second quarter (2Q) of this year as uncertainties sparked large outflows among foreign investors following the country’s 14th general election that saw a change in government for the first time since independence.
4863 6888 4065 AXXTF MYTEF 3034 5168 GEBHF HRGHY
KUALA LUMPUR (June 20): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (June 21) may include the following: Kimlun Corp Bhd, Scientex Bhd, MyEG Services Bhd, Gabungan AQRS Bhd, Barakah Offshore Petroleum Bhd, Dagang NeXchange Bhd, GHL Systems Bhd, Malaysian Resources Corp Bhd, Tan Chong Motor Holdings Bhd, myNEWS Holdings Bhd and Hap Seng Consolidated Bhd.
5226 4456 7251 5148 4405 BSMAF 3034 0021 1818
KUALA LUMPUR (June 18): The FBM KLCI pared some of its losses at the midday break and was down 0.78%, with tepid sentiment tracking losses at the regional markets.
APEXF 7251 7090 7113 BATS TPGVF 4162 3034 KLKBY 5226 5347 3301 TNABY AXXTF HRGHY 5681 2291 1163 5168 TGLVY 2445 1996 6888 5819 TNABF
Hap Seng Consolidated Bhd (+ve) TRADING of the shares in Hap Seng Consolidated Bhd (fundamental: 1.3/3, valuation: 1.3/3) triggered our momentum algorithm last Thursday for the first time this year. The group saw 937,700 shares traded.
5138 1996 3034
KUALA LUMPUR (June 18): The FBM KLCI fell 1.13% in early trade this morning, tracking losses at most regional markets spooked by the U.S.-China trade wars.
PBLOF 4065 5681 1295 3034 KLKBY 2445 4588 3867 1996 6888 5819 AXXTF
KUALA LUMPUR (June 14): theedgemarkets.com highlighted six stocks with momentum at Bursa Malaysia's afternoon market close today. Three stocks displayed positive momentum while another three showed negative momentum.
4634 BSMAF 3034 1818
KULIM, June 10 — The 23-year wait by 206 former workers of Padang Meiha Estate finally ended when they received the first part of three compensations promised by the estate’s former management.
KUALA LUMPUR: Hap Seng Consolidated Bhd (Hap Seng) plans to dispose of its 100 per cent interest in HSC Sydney Holding Ltd and a 20 per cent stake in Hap Seng Credit Sdn Bhd, for RM771.16 million and RM906 million respectively, to Lei Shing Hong Capital Ltd. In a filing with Bursa Malaysia today, Hap Seng said the disposal of HSC Sydney would enable the company to pare down borrowings and channel part of the proceeds towards working capital requirements.
BSMAF 3034 1818
KUALA LUMPUR: Dutch Lady Milk Industries Bhd , Kuala Lumpur Kepong Bhd (KLK) Hap Seng Consolidated Bhd , Protasco Bhd , Vertice Bhd and Westports Holdings Bhd are among the stocks to watch, according to JF Apex Research.
KLKBY 2445 3026 5246 3034
“The proposed acquisition enables the Hap Seng group to participate in the wholesale distribution of the Mercedes-Benz and Fuso commercial vehicles in the growing market in Malaysia,” it said in a filing with Bursa Malaysia yesterday.
BSMAF 3034 1818
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...